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Abstract
Over a period of 3 years, the European Union’s Innovative Medicines Initiative WEB-RADR (Recognising Adverse Drug 
Reactions; https ://web-radr.eu/) project explored the value of two digital tools for pharmacovigilance (PV): mobile applica-
tions (apps) for reporting the adverse effects of drugs and social media data for its contribution to safety signalling. The ulti-
mate intent of WEB-RADR was to provide policy, technical and ethical recommendations on how to develop and implement 
such digital tools to enhance patient safety. Recommendations relating to the use of mobile apps for PV are summarised in 
this paper. There is a presumption amongst at least some patients and healthcare professionals that information ought to be 
accessed and reported from any setting, including mobile apps. WEB-RADR has focused on the use of such technology for 
reporting suspected adverse drug reactions and for broadcasting safety information to its users, i.e. two-way risk communica-
tion. Three apps were developed and publicly launched within Europe as part of the WEB-RADR project and subsequently 
assessed by a range of stakeholders to determine their value as effective tools for improving patient safety; a fourth generic 
app was later piloted in two African countries. The recommendations from the development and evaluation of the European 
apps are presented here with supporting considerations, rationales and caveats as well as suggested areas for further research.
 * Peter G. M. Mol 
 p.g.m.mol@umcg.nl
Extended author information available on the last page of the article
Key Points 
A mobile application (app) designed for adverse drug reac-
tion (ADR) reporting and product safety alerts can help to 
augment pharmacovigilance activities and extend a health 
authority’s reach to patients and healthcare professionals.
Of particular value to app users was the ability to learn 
about the safety profiles of medicines through user-
friendly, interactive graphics within the app as well as 
privacy and data protection features.
While uptake and use of the app to date seems modest in 
comparison with other ADR-reporting modalities, it is 
reasonable to expect that app-based reporting will grow 
in importance as a younger generation of app-literate 
patients matures and smartphone owners increasingly 
use their mobile devices to access the Internet.
1 Introduction
The Innovative Medicines Initiative (IMI) WEB-RADR 
(Recognising Adverse Drug Reactions) consortium was 
a public–private partnership supported by the IMI Joint 
Undertaking (http://www.imi.europ a.eu) under Grant 
Agreement no 115632. Participating members were from 
European regulatory agencies, the pharmaceutical indus-
try, academia, patient groups and other organisations 
with an interest in pharmacovigilance (PV). The aim of 
WEB-RADR was to develop and evaluate two digital 
tools to support PV activities and promote patient safety, 
and ultimately provide policy, technical and ethical rec-
ommendations on implementing such technology. Full 
details of IMI WEB-RADR’s objectives and approaches 
have been detailed elsewhere [1]. The outputs from WEB-
RADR arose from four work packages: two work packages 
undertook original research in social media and mobile 
application (app) technology; a third evaluated the scien-
tific impact of the original research to determine where it 
had potential to add value to existing PV methodologies. 
A fourth work package addressed governance and policy, 
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including personal data protection and ethical and societal 
considerations related to the use of mobile apps and social 
media for PV. This paper will focus on recommendations 
resulting from the work on apps. Recommendations result-
ing from the research conducted using social media will 
be the subject of a separate publication.
The profusion of smartphones and other mobile devices 
offers an opportunity to further engage the public in report-
ing suspected adverse drug reactions (ADRs) to national 
competent authorities (NCAs) and to improve communica-
tion of emerging safety issues from NCAs to the public and 
healthcare professionals (HCPs). Together with web-based 
forms, mobile devices offer a platform for developing real-
time PV systems that can enable near-instantaneous trans-
mission of patient safety information at the point of need, 
potentially improving health outcomes. Data collection in 
PV typically relies on voluntary reporting of suspected 
ADRs submitted to NCAs and pharmaceutical companies 
by HCPs. Over the last 20 years, patient reporting has been 
increasingly recognised as a valuable addition to safety 
monitoring activities [2, 3]. This growing interest in the 
patient perspective has coincided with a proliferation of 
technology, which in turn has increased access to data, 
accelerated information exchange, and fostered transpar-
ency. It is therefore reasonable to assume that efforts to 
improve ADR reporting and patient safety communication 
could benefit from the adoption of new technologies such 
as mobile apps.
Early experiences with mobile apps for medical product 
safety have been promising and have demonstrated poten-
tial for broad engagement of the public in safety reporting 
[4]. At the same time, concerns over security and poten-
tial for misuse of personal data have grown with several 
well-publicised breaches such as those at Yahoo, CEX and 
Facebook [5–7]. Aside from developing and evaluating 
digital tools themselves, the WEB-RADR project also 
examined the ethical, societal and privacy concerns related 
to mobile apps, as well as technological and promotional 
aspects, from a European perspective.
The WEB-RADR mobile apps were designed to facili-
tate instantaneous reporting of suspected ADRs directly to 
NCAs by patients and HCPs, as well as timely dissemina-
tion of accurate PV information from NCAs to HCPs and 
the public, thereby allowing potential two-way exchange of 
safety information. The apps have been made freely avail-
able by PV centres in the United Kingdom (UK; Medicines 
and Healthcare products Regulatory Agency [MHRA]), 
the Netherlands (NL; Lareb), and Croatia (HR; HALMED) 
in both Google Android and Apple iOS formats; links to 
download the apps are available at https ://web-radr.eu/mobil 
e-appli catio ns-for-adr-submi ssion . A fourth version of the 
app has been piloted in Burkina Faso and Zambia in col-
laboration with the World Health Organization (WHO); at 
the time of writing, this fourth version was still undergoing 
validation and assessment.
The use of mobile apps for ADR reporting and the down-
stream use of these data for PV is a relatively new and unex-
plored concept. The anticipated impact of these apps will 
depend on the degree of uptake by the public and HCPs, 
the quality and volume of ADRs reported, and the utility of 
the data in safety signal detection and evaluation. In WEB-
RADR, each NCA devised its own strategy for mobile app 
promotion best suited to its national context and providing 
a range of engagement models for assessment. Focus group 
discussions and face-to-face interviews were conducted with 
potential app users from multiple countries [8]. Enthusiasm 
for the app was high and the feedback received was con-
structive, targeted and generally encouraging. Comments 
from the participants have been used to inform further app 
development to improve uptake and encourage continued 
use of the app. As of 31 December 2017, there have been 
over 17,000 app downloads and 838 suspect ADR reports 
received since the first app was launched on 14 July 2015 
(Table 1).
To integrate ADR reports submitted via the apps into 
existing ADR processing workflows at NCAs, a direct con-
nection was made between each app and the respective 
NCA’s existing electronic gateway. When a user submits an 
ADR report through the app, the reported data are auto-
matically converted into standard International Council for 
Harmonisation of Technical Requirements for Pharmaceu-
ticals for Human Use (ICH) E2B(R2) format, allowing it 
to be submitted directly to the NCA’s PV portal for triage, 
assessment and signal detection alongside ADR reports 
received through other reporting channels. The apps also 
provide a means for NCAs to broadcast to users personal-
ised safety alerts and news about user-selected drugs. App 
users can also explore aggregate ADR report information in 
interactive graphs that display volumes of reports received 
by the NCA (at the national level in the UK and NL and 
at the global or EU level for HR) for medicines of interest 
according to Medical Dictionary for Regulatory Activities 
 (MedDRA®; https ://www.meddr a.org) system organ class 
and, where available, by patient demographics such as age 
and sex. NCAs submitted suspected ADRs from the mobile 
apps to EudraVigilance by batching app reports with reports 
submitted through other channels, in accordance with usual 
reporting requirements [9].
The following recommendations1 relate to policy consid-
erations and original research pertaining to the development 
1 The non-binding recommendations presented in this report repre-
sent the views of the authors and do not represent the views or poli-
cies of the authors’ respective affiliations (unless by coincidence), 
even if employees of those organisations at the time of preparing this 
paper.
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and utility of a mobile app platform for PV conducted under 
the auspices of the IMI WEB-RADR project between Sep-
tember 2014 and September 2017. In total, we present 27 
separate recommendations with the intention of informing 
PV professionals, particularly those with an interest in the 
development of digital technologies to enable PV.
2  Summary of the Research 
and Recommendations
The recommendations outlined in this paper have been 
developed based on evidence from the activities undertaken 
through IMI WEB-RADR. For a full description of the stud-
ies, refer to the cited original publication or technical report. 
For the sake of brevity, unless explicitly stated to the con-
trary, the terms ‘mobile app’ (or simply ‘app’) are used to 
cover software designed for mobile devices, irrespective of 
the means of presentation, i.e. via a smartphone or a tablet. 
Recommendations were drafted by the authors of the vari-
ous outputs that collectively described the outcomes of the 
app work package. Draft recommendations were subjected 
to several rounds of review by other work package mem-
bers, resulting in either their revision or rejection. Recom-
mendations were typically rejected on the grounds that they 
were too general in nature or not adequately supported by 
insights arising from the work of WEB-RADR or if they 
were considered not implementable in practice. Final-draft 
recommendations were circulated to the WEB-RADR Gen-
eral Advisory Board2 for review and comment. Finally, all 
consortium participants were invited to review a mature 
draft of this paper.
2.1  Drivers for Mobile Application Development 
and Other Pre‑development Considerations
Prior to committing the effort and investment needed to 
develop any mobile app, it is important to gain an under-
standing of the setting in which the app is to be used and 
the intended target group. Prior knowledge of technical 
and regulatory limitations and likely barriers to uptake and 
usage can inform app design and implementation. The rec-
ommendations provided in this section could be deemed 
good practice for app development in any setting; however, 
it is pertinent to share the specific experiences from WEB-
RADR as a means of emphasising the value of undertaking 
a scoping exercise prior to full-scale app development. The 
value versus opportunity cost of app development has not 
been factored into these recommendations since it is likely 
to vary from country to country given differences such as 
availability of established means of ADR reporting, infra-
structure maturity (internet, mobile networks, etc.), educa-
tion and awareness of healthcare systems generally and PV 
more specifically.
Consideration of the intended use of the technology is 
also important. For example, the key benefits in the EU set-
tings evaluated were related to easy access to trusted reg-
ulatory information and the impact in terms of reporting 
considered additive to the suite of tools available to report-
ers [8]. However, early feedback from the pilots in Burkina 
Faso and Zambia points to the value of off-line functionality 
(reporting and news) independent of access to a website.
Furthermore, there are efficiencies in the costs associated 
with standardised/shared platforms/code, with significantly 
reduced maintenance costs associated with the app version 
used in Burkina Faso and Zambia developed towards the 
end of the WEB-RADR project. Technology now enables 
the use of common code to deliver the same functionality 
or multiple modalities; this offers a more flexible and cost-
effective framework to deliver on user needs independent 
of the end user device. See Table 2 for app development 
recommendations.
Table 1  Breakdown of app 
downloads and reported ADRs 
by country to 31 December 
 2017a
ADR adverse drug reaction, app application, MHRA Medicines and Healthcare products Regulatory 
Agency
a As of Q4 2017, mobile operating system penetration within these three countries was as follows: UK: 
Android 46.7%, iOS 50.6%; the Netherlands: Android 56.0%, iOS 41.9%; and Croatia: Android 82.3%, iOS 
15.0%. See http://gs.statc ounte r.com/os-marke t-share /mobil e
United Kingdom 
(MHRA)
Netherlands (Lareb) Croatia (HALMED)
Date of app launch 14 July 2015 29 Jan 2016 18 May 2016
Number of ADR reports 505 173 160
App downloads for iOS 7498 4172 422
App downloads for Android 2701 2497 876
2 The General Advisory Board (GAB) consists of experts from 
organisations that are independent of those delivering and managing 
the project, as well as work package leaders. The GAB has an impor-
tant role, providing advice on the WEB-RADR project, and identify-
ing other initiatives which may be relevant to the project. For further 
details see https ://web-radr.eu/gover nance /.
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2.2  Mobile Application Design
Traditional reporting mechanisms require significant time 
and effort to complete and submit, inhibiting ADR report 
submission to Marketing Authorisation Holders (MAHs) 
and regulators [14]. Mobile app design for PV offers the 
opportunity to improve upon traditional ADR-reporting 
forms for patients and HCPs alike. The app design process 
in WEB-RADR focused on developing an uncluttered visual 
design incorporating feedback from patient and HCP groups, 
while maintaining enough consistency to enable comparison 
with suspected ADRs obtained through other mechanisms. 
Since the reports submitted through the app would be passed 
along to NCAs, the app screens had to include the minimum 
necessary data fields to comply with ICH E2B(R2) standards 
and requirements in line with the guideline on good phar-
macovigilance practices (GVP) Module VI, which served 
as one of the starting points for their design [15]. The four 
mandatory reporting elements were the focus of data col-
lection: (1) patient information, (2) reporter information, 
(3) suspected medicinal product and (4) suspected adverse 
reaction.
The digital platform afforded opportunities to have 
adaptive forms. Since ADR reports contain information 
about medical products and ADRs, structured report fields 
may require knowledge of medical terminology; however, 
it is unlikely that all patients will be familiar with this 
type of vocabulary. In the UK, work was done as part of 
Table 2  Recommendations for application (app) development
Recommendation Rationale
Prior to designing a mobile app, it is recommended that smartphone and 
device use among target populations is assessed as this can inform 
basic decisions regarding development
Decisions over which reporting modalities (e.g. app, website, etc.) and 
operating systems are supported should account for the prevalence 
of wired versus wireless connectivity and the devices in use (e.g. 
iOS vs Android vs PC) in the target setting. An evaluation should be 
conducted to ensure that the platform proposed is the most effective 
means of delivering the functionality to the target audience
For example, smartphone penetration and use of different types of 
devices vary greatly from country to country. Android devices are 
more commonly used in Europe, South America, and Asia, while 
iOS devices are more commonly used in Australia and in North 
America, use of both operating systems is broadly even [10]. Addi-
tionally, while two-thirds of the global population use the Internet or 
own a smartphone, this is less common among adults in Africa and 
South Asia [11]
Organisations deploying apps should be aware of the differing regula-
tions in different regions and countries
The General Data Protection Regulation (GDPR) introduces EU-wide 
legislation on personal data and security and developers of apps 
need to be familiar with the rules and obligations. In particular, they 
should assess the impact of data protection at the time of design 
concept and review compliance periodically. In addition, an ePrivacy 
Regulation has been proposed [12]. It is also important that develop-
ers pay attention to any specific national requirements, and testing of 
application security is advised
Other regulations should be considered. Although the apps developed 
by WEB-RADR are not currently impacted by EU Medical Device 
regulation, it would be advisable to maintain awareness of device 
regulations, particularly if the apps were to be enhanced to an extent 
where medical device regulations may become relevant. In case of 
doubt, legal advice should be sought [13]
Any new app or subsequent updates to the app or operating platform 
should be extensively tested before release to ensure that technical 
issues are avoided and to assure the app design remains intuitive, does 
not inhibit usage and minimises user error
A survey indicated that users experienced difficulties downloading 
some versions of the app. New software requires testing and valida-
tion to ensure that it will perform as expected on release. A formal 
validation model requiring user specification and technical specifi-
cation tested using a formal validation strategy with a final report 
should be employed
Consultation with target user groups should be considered when under-
taking app development efforts for pharmacovigilance
Prior to app launch, WEB-RADR had access to patients who contrib-
uted important suggestions based on their experience testing the app 
prototype. Focus groups and face-to-face interviews were conducted 
in multiple countries where feedback was documented formally to 
later inform app design [8]. Consultation may be less important if 
targeting well characterised populations of users or similar geo-
graphic regions
Recommendations on the Use of WEB-RADR Mobile Apps
WEB-RADR to investigate the use of patient-friendly Med-
DRA® terms for reporting ADRs, and a list of patient-
friendly terms is available on the MedDRA Maintenance 
and Support Services Organization (MSSO) website [16].
There are also several features that could be integrated 
into an app to facilitate processing and analysis by NCAs, 
including structured and hierarchical event ontologies. Auto-
fill features, an adaptive suggestion that appears in a field 
automatically when a user types a few letters, for symptoms 
and product names may expedite the report submission pro-
cess and ensure that these data points are spelled correctly 
and adhere to standardised terminologies.
While structured text fields such as drop-down menus or 
radio buttons promote data standardisation, these may not 
be ideal in every situation. For example, patients may not 
comprehend ontology-based medical terms suggested in a 
drop-down menu or they may find that the options do not 
best describe their experiences. From a cognitive design per-
spective, overly structured fields may negate useful nuance 
in the patient’s experience, reducing the usefulness of the 
report. Early testing suggested that patients may find that 
completing free-text fields to describe ADRs in their own 
words preferable to selecting options from drop-down menus 
with multiple choice and radio buttons [17]. Such design 
considerations can conceivably impact report completeness 
and accuracy.
It is important to ensure that a mobile PV app can be used 
by as wide a population as possible. Technology industry 
standards can provide guidance on design elements such as 
preferred font size for legibility, preferred colours or shades 
for text and image visibility and button placement for touch-
screens. Adhering to such standards as much as possible 
ensures that a mobile app can be used by patients and HCPs 
with a variety of abilities. Additionally, when designing an 
app for ADR reporting, any constraints imposed by regula-
tory requirements, database or technology limitations and 
resource implications should be carefully evaluated.
Beyond the visual design of the app, the digital envi-
ronment permits the creation of a positive feedback loop 
whereby reporters receive confirmation and positive rein-
forcement for submitting their report via email or in-app 
messaging. In early experiences with PV reporting, such 
feedback mechanisms were believed to have improved the 
user experience [4]. This also creates a conduit for follow-up 
reporting to NCAs as well as a mechanism for push notifi-
cations when new safety alerts are issued by NCAs. Some 
elements of this approach to enhancing user engagement 
were assessed in WEB-RADR.
Since the base WEB-RADR mobile app was to be 
deployed in multiple countries, yet evaluated centrally by 
the project, a certain level of design flexibility was required 
to allow country-specific language and branding. In some 
countries the NCA’s ADR-reporting programme already has 
a recognisable identity and the app was therefore designed 
to be extensible with colours, logos, etc. to mimic extant 
reporting forms and branding. See Table  3 for design 
recommendations.
2.3  Mobile Application Content and Data‑Related 
Considerations
The WEB-RADR app has been developed to improve the 
two-way exchange of information (i.e. the reporting of ADRs 
and the provision of patient safety information). Therefore, 
the app contains an information-sharing component and an 
ADR-reporting component. The information-sharing com-
ponent enables app users to receive safety alerts and news, 
as well as view aggregated statistics on previously reported 
ADRs.
A qualitative study that involved focus group discussions 
and face-to-face interviews showed that patients and HCPs 
were generally positive about the existing content of the app 
and suggested some additional functions that could also 
be useful [8]. Perspectives on the content of the app were 
further assessed in a large online survey among patients 
and HCPs in Europe [22]. It was shown that potential app 
users were somewhat more interested in an app for two-
way exchange of safety information than in an app that only 
served one purpose (i.e. either just the information-sharing 
component or just the ADR-reporting component). The sur-
vey provided many suggestions on how to further improve 
the app to increase ADR reporting to NCAs.
A second online survey was conducted among current 
users of the WEB-RADR app. The survey asked about their 
experiences with the app. Most responders had a positive 
view of the value of the app in general, for both the ADR-
reporting feature and the patient safety information provided 
in the app. Some suggestions were also received on how to 
further improve the app.
A quantitative survey study found that respondents from 
different countries preferred access to different types of infor-
mation, e.g. drug stock levels (Croatia), alternative medicines 
(the Netherlands), and ADR mitigation strategies (the UK). 
Information on newly identified drug–drug interactions was 
of common interest across the three countries surveyed [8, 
22]. This echoes our earlier recommendation in the pre-devel-
opment considerations section (Sect. 2.1): when determining 
what kind of information to provide to users in the app, con-
sideration should be given to user- and country-specific con-
tent. Interests among different user groups could differ, and 
countries may vary greatly in terms of what safety information 
may need to be broadcast; for example, local regulatory com-
munication of newly identified drug–drug interactions may 
vary where there are formulary differences across countries. 
See Table 4 for a summary of the recommendations regarding 
content and data-related considerations.
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Table 3  Recommendations for application (app) design
Recommendation Rationale
General design recommendations applicable to health apps
 If a mobile app is to have different target groups (e.g. HCPs and 
members of the public) customisation for each target group should 
be considered
WEB-RADR explored the use of different report designs tailored for 
different types of users. For example, the users of the UK’s Yellow 
Card app can select MedDRA terms from a drop-down list to describe 
their ADR, ensuring that the reaction data are already coded when 
they are submitted to the MHRA. For the patient version, the MHRA 
is currently exploring ways to make this feature easier for patients to 
use with a patient-friendly MedDRA list that contains descriptions 
of medical concepts in layman’s terms [17, 18]. Additionally, distinct 
questions could be presented to different types of users who may be 
more likely to be able to provide certain details; for example, a patient 
may be able to report that a medical product was purchased from an 
Internet pharmacy, whereas that patient’s HCP may not have that level 
of knowledge
 If different versions of a mobile app are needed to best meet the 
differing needs of multiple target groups, it is recommended that a 
single app prototype is developed with as many standard features as 
possible. This can then be configured at lower overall cost
In WEB-RADR, three apps were developed for three pilot member 
states, all sharing a similar framework. Ultimately, for the second and 
third pilots in the Netherlands (Lareb) and Croatia (HALMED), the 
NCAs worked together to determine a set of common design stand-
ards to create a more generic app that would require less development 
than the first pilot in the UK (MHRA). The Lareb app was developed 
and launched 6 months after Yellow Card; the HALMED app was 
developed and launched 3 months after Lareb
The lower cost of using established applications has contributed to roll-
out of the app to lower income countries; see the WEB-RADR portal 
(https ://webra dr.files .wordp ress.com/2017/09/web-radr-stake holde 
r-event _theme 2.pdf)
 In order to provide a user-friendly experience for as many users as 
possible, ensure that the app design complies with accessibility 
requirements or industry best practices that facilitate use of the app 
among patients and HCPs with different abilities
Best practices exist for ensuring maximum accessibility through web 
and app design. Both Apple and Android devices have documented 
design principles for developers [19, 20]. In addition, the European 
Commission has published a set of Web Content Accessibility Guide-
lines from the Web Accessibility Initiative [21]. Furthermore, many 
modern devices and operating systems have built-in accessibility 
features. It will be necessary for app developers to understand how the 
app can take advantage of and interact with these features, rather than 
ignore or override them
 The mobile app should give users the option of receiving push noti-
fications from the health authority or PV centre when new safety 
information is available
In a quantitative survey study, more than half of respondents indicated 
interest in an optional push notification feature [22]. However, not all 
users expressed interest in this feature, for example, patients in Croatia 
were generally less interested, and there were also national differences 
in preference amongst HCPs
 Mobile apps that provide safety information should include the abil-
ity for the user to configure or customise the type of information 
that s/he receives (e.g. information at the individual product level or 
the therapeutic area level)
The quantitative survey study found that users were interested in receiv-
ing safety news regarding a wide variety of medicines. HCPs gener-
ally preferred to receive information on all approved drugs, while the 
largest group (40%) of patients preferred to receive only information 
pertaining to their own prescriptions [22]
 Mobile apps for ADR communication should provide users with the 
option of bypassing the login screen to automatically access the app 
after the information has been entered once
The quantitative survey study and feedback from the Netherlands app 
indicated that most patients and professionals preferred to access 
the app without having to login each time they opened it (57% and 
70%, respectively) [22]. In addition, respondents to a user experience 
survey indicated that they would prefer not to create an account or 
enter login details. Providing patients and HCPs with the option to 
choose whether to login automatically would allow users to access the 
app quickly and easily—removing a hurdle to real-time ADR report-
ing and facilitating quick access to timely medicine news. However, 
should app developers choose to take this approach, they should work 
closely with stakeholders to determine the appropriate level of patient 
consent or privacy protection required for app functions that will not 
require password protection
Recommendations on the Use of WEB-RADR Mobile Apps
Table 3  (continued)
Recommendation Rationale
 Mobile apps for ADR communication should be designed with the 
possibility to integrate with other health/drug safety applications 
and/or systems through, e.g. APIs, since this will extend their 
uptake by a wider range of organisations and a larger group of 
users, consequently enhancing sustainability
Several organisations including NHS trusts, EHR system providers and 
developers of health apps have approached MHRA with an interest in 
integration of different components of the WEB-RADR app into their 
own platforms. Their rationale is that such an approach enables them 
to provide validated forms or data in a format agreed by the regula-
tory authority, but without the need for them to develop, maintain and 
update the code themselves
Specific design recommendations applicable to ADR-reporting apps
 At a minimum, mobile reporting apps should provide an immediate 
acknowledgement message indicating that an ADR report has been 
successfully received
Many responders to both a quantitative survey study and a qualitative 
study expressed interest in receiving feedback or a confirmation fol-
lowing ADR report submission. Users appreciated that, upon report 
submission, the WEB-RADR apps displayed a simple notification 
informing the user that the report had been successfully sent. Earlier 
research by Lareb indicated a simple acknowledgement of receipt 
would satisfy most reporters [23]
Some users indicated that additional types of feedback would be appre-
ciated (e.g. an overview of how frequently the ADR had been reported 
previously; feedback on what was done with the report), while 
others preferred to not receive this type of response as they found it 
intrusive. Therefore, giving users the option to select their preferences 
regarding ADR feedback within the app ought to be considered [8]. 
Also see experiences from the SCOPE project for feedback on report 
templates from reporters [24]
 Mobile apps for ADR reporting should be designed with an emphasis 
on two-way information exchange features, as this may encourage 
adoption and increase the likelihood of continuous user engage-
ment and repeated use of the app
Findings from a qualitative study revealed that patients would view the 
news feature in the app favourably. Patients indicated that they might 
use the app as a quick and accessible source of information about 
various ADRs. For example, 84% of patients and 71% of HCPs speci-
fied that they would want to receive safety notifications on medicines 
from their local NCA [22]
 When considering which functionalities to add to an app targeting 
HCPs, it is suggested to focus on features that facilitate the provi-
sion of safety information rather than features facilitating ADR 
report submission
According to the quantitative study, HCPs expressed a greater interest 
in app features that would provide them with safety information than 
features that would enable ADR reporting [22]
 Strive for a report form design that captures all essential informa-
tion in a user-friendly manner. For instance, free-text fields may be 
more appropriate for some questions than drop-down menus with 
a long list of options. It may be possible to reduce the time it takes 
to complete a report by keeping mandatory fields to a minimum. 
User-friendly phrases and descriptions may help to ensure that 
ADR reports are as accurate and complete as possible
Lareb operates a web-based ADR report form that includes many struc-
tured fields (e.g. radio buttons, drop-down menus). While this ensures 
data completeness, Lareb has also received complaints from users that 
reporting is time consuming. In addition, patients might find that their 
experiences are not well reflected in drop-down menu options and 
may find it preferable to provide this custom information themselves
In order to keep the length of the ADR-reporting form to a minimum, it 
was shown that a shortened form in the app still produces reports with 
sufficient clinical quality. The proportion of reports of at least moder-
ate quality was high in both user groups (HCPs and patients) for all 
countries, but relatively lower for app reports: 83% vs 92% in the UK 
(p = 0.08); 85% vs 98% in the Netherlands (p < 0.01); and 78% vs 78% 
in Croatia (p = 1.0) [25]
Although free-text fields may provide patients and HCPs with the 
opportunity to describe ADRs in their own words, unstructured text 
resulting from these fields will need to be automatically coded or may 
require additional manual review [25]
 For mobile apps aimed at HCPs, it is recommended to keep adverse 
reaction report forms concise and clinically focused, in contrast to 
those provided for patients
The qualitative study found that time constraints were more likely to be 
a barrier to ADR reporting among HCPs than among patients [8]
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2.4  Mobile Application Implementation, Awareness 
and Uptake
NCAs can use various strategies to inform potential users 
about the existence of the mobile app, but it is most efficient 
to use those channels and sources that reach the audience with 
potentially the highest interest in the app.
To assess which patients and HCPs are most interested in 
an app with capabilities for the two-way exchange of safety 
information, data from a European-wide online survey study 
were used [22]. In the survey, patients and HCPs were asked 
to what extent they were interested in the app. Analyses of the 
HCP data showed that HCPs who already (at least sometimes) 
use a health app were very interested in the app. This was 
also shown among the patients. In addition, patients that were 
younger were very interested in the app.
See Table 5 for a summary of recommendations on imple-
mentation, awareness and uptake.
Table 3  (continued)
Recommendation Rationale
 The ability to add attachments to reports is considered valu-
able—with the implementation of the ICH E2B(R3) format, this 
will become feasible and should be considered for future apps or 
upgrades
Mobile devices typically have built-in cameras, potentially making 
it easy for app users to include a photo or video along with ADR 
reports. Photos or videos could help capture product information 
(brand name, batch number, barcode) or provide a visual reference for 
certain ADRs (e.g. a photo of a skin rash, a video recording move-
ment related to dyskinesia). For several years, Lareb has allowed 
reporters to attach additional files to ADRs submitted via web-forms. 
This not only decreases the burden on the reporter by allowing a 
simple way to relay medical information (e.g. uploading a medication 
list or a discharge letter from the hospital), but also increases Lareb’s 
understanding of the experienced ADR. The ICH E2B(R3) format 
that supports the transmission of additional files was not available 
for use during the WEB-RADR project. It follows that changes to 
databases and appropriate processes for receipt and analysis of such 
data would be needed to exploit information captured through these 
device features
ADR adverse drug reaction, API application programming interface, EHR Electronic Health Record, HCP healthcare professional, ICH Interna-
tional Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, MedDRA Medical Dictionary for Regulatory 
Activities, MHRA Medicines and Healthcare products Regulatory Agency, NCA national competent authority, NHS National Health Service, PV 
pharmacovigilance, SCOPE Strengthening Collaboration for Operating Pharmacovigilance in Europe
Table 4  Recommendations regarding application (app) content and data-related considerations
ADR adverse drug reaction, NCA national competent authority
Recommendation Rationale
The ability to access all information contained in Patient Information 
Leaflets (or Product/Patient Package Inserts) should be considered as 
an additional feature of any app designed for patient use
The quantitative survey study found that patients who were interested 
in other app functions expressed most interest in being able to use the 
app to access both Patient Information Leaflets and an overview of 
previously reported ADRs, when presented with both these possibili-
ties [22]. However, this approach should only be considered where the 
information can be appropriately formatted and indexed for use on a 
mobile device
The app should provide users with the ability to access, save a draft 
and review their own submitted reports as well as summary informa-
tion regarding ADRs previously reported to the NCA
Users preferred having the ability to look at their previous ADR reports. 
In addition, patients indicated that a major benefit of the app would be 
if it allowed them to check whether a symptom has previously been 
reported as an ADR. Several studies have shown that patients are 
sometimes uncertain about an association between a symptom and a 
drug and having this information in the app could reduce their uncer-
tainty about an association between a drug and their symptoms [8, 22, 
26–29]. To respect users’ desire for anonymity, however, there should 
exist an option not to store personal details when saving a report
Apps should provide information to users about the importance of 
ADR reporting. For patients, this should contain an explanation of 
its importance for patient safety and that the information they volun-
tarily submit can benefit other stakeholders
The quantitative study found that patients were mainly motivated to 
report ADRs to contribute to patient safety knowledge and to share 
their experiences for the benefit of others [22]
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2.5  Mobile Application Impact and Miscellaneous 
Recommendations
The recommendations presented in Table 6 relate to the 
assessment of the overall impact of mobile reporting apps 
for PV and other stand-alone recommendations.
3  Discussion
A series of recommendations relevant to the development of 
mobile apps for the reporting of ADRs are presented with 
the intention of informing PV professionals and other stake-
holders, particularly those with an interest in the develop-
ment of research methods and digital technologies. Each 
recommendation is based on the experiences and outcomes 
of the research conducted under the auspices of IMI WEB-
RADR. Collectively, the recommendations should not be 
considered a comprehensive treatise on the subject, rather 
they should be considered within the context of the entire 
corpus of research and regulatory guidance documents that 
exist outside of IMI WEB-RADR.
Since the start of the WEB-RADR project, mobile ADR-
reporting apps have been launched in five separate coun-
tries. This group of participating countries has presented 
both diverse target populations of HCPs and non-HCP users, 
predominantly patients, as well as widely varying reporting 
systems and diverse technical resources that have impacted 
how each app has been configured. It is our hope that, hav-
ing launched these apps in five unique settings, the recom-
mendations, when taken together with their caveats, will be 
applicable to many other settings. That said, careful consid-
eration should be given to the generalisability of the recom-
mendations in circumstances that are substantially different 
from those described in the original research.
Overall, our experience has indicated that a deep under-
standing of the target app-user population, through local 
knowledge and potential user outreach prior to embarking 
on development activities, can facilitate effective design 
from the start. However, it is equally important to continue 
improving the app based on user feedback and evaluation 
of outputs after any public release—particularly following 
initial launch and major updates. Additionally, preferences 
and needs for patient safety information and reporting can 
vary greatly among different groups, and a balance must be 
struck between providing enough features that are useful to 
a wide range of users without attempting to create an app 
that ‘does it all’.
Communication in support of the launch of the app is 
important, followed by further provision of information at 
appropriate intervals to keep stakeholders informed about 
enhancements and new features of the software. Once estab-
lished, a good place to inform patients about the app is at 
Table 5  Recommendations on application (app) implementation, awareness and uptake
HCP healthcare professional, NCA national competent authority, SCOPE  Strengthening Collaboration for Operating Pharmacovigilance in 
Europe
Recommendation Rationale
Prior to app launch, host organisations should devise a publicity strat-
egy to inform HCPs and the public of the app and encourage uptake. 
Continuously publicising the app over a longer period—and not just 
following app launch— may also serve to encourage app uptake
The Yellow Card app was launched in July 2015, and the highest 
number of app users registered around this time. The second-highest 
number of registrants occurred Sept 9–10, 2015, immediately follow-
ing a brief update about the app on the gov.uk website [30]. Similarly, 
the Lareb app was launched at the end of January 2016. While the 
highest number of users registered immediately following the launch 
in February 2016, there was a second surge of app registrants in April 
following an article published in a Dutch nursing magazine [31]
The app should be hosted by an organisation that is trusted by and 
preferably familiar to its target users. If not familiar, steps should be 
taken to increase awareness of the host organisation in the peri-
launch period. For example, the app could be promoted to HCPs via 
NCAs and/or professional bodies
A qualitative study found that respondents would be more likely to use 
an app that was associated with a familiar and trustworthy source [8]
NCAs and professional bodies are preferred senders of risk information 
for professionals. Information about the app seems to be sufficiently 
related to that topic to apply the findings of the SCOPE survey [24]
Efforts to inform HCPs and patients about the app should focus on 
those who use other health apps. Hence, it is likely to be beneficial to 
advertise the app in other health apps
Patients and HCPs who already use other health apps were more inter-
ested in the app than those that did not use other health apps. It was 
also shown that younger patients tended to be more interested in the 
app [22]
Country-specific communication plans should be developed Possible channels and sources for promoting the app will differ per 
country; therefore, country-specific strategies are needed. In the quan-
titative survey study, there were quite a few patients who had never 
heard of their national agency [22]
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first prescription or first dispensing of a medicine. Patients 
are most likely to experience ADRs when starting new medi-
cations [32].
It is important to note that even if an app for ADR report-
ing is well-designed and user-friendly, it will not serve its 
purpose if the target population is not familiar with that 
purpose. Patient awareness of reporting ADRs is therefore 
critical to adoption and utilisation of the app and may be a 
factor beyond the scope of designing and developing the 
app itself. It might be necessary to raise public awareness 
of ADR reporting prior to evaluating the need for an app; 
in other cases, the existence of a mobile app could serve to 
drive awareness of ADR reporting among the public, and it 
may be useful to address underreporting barriers, as part of 
a publicity strategy. More research is needed to explore ways 
to encourage patient reporting of ADRs in a balanced way 
that does not lead to bias or soliciting.
Since release, each app has seen varying degrees of expo-
sure. The Yellow Card mobile app was launched as an exten-
sion of MHRA’s Yellow Card Scheme—a safety reporting 
programme for human medicinal products that has been 
running for over 50 years. To date, MHRA has received 505 
ADR reports through its mobile app, launched in July 2015 
(see Table 1). Objectively speaking, this number pales in 
comparison to the 26,000 ADR reports the MHRA received 
in 2016 directly from HCPs and the public, and there is a 
tendency to view this as a shortcoming of the mobile app 
itself [33]. However, the value identified by users was much 
broader than just reporting and extended to engagement with 
the wider PV system and accessing timely safety informa-
tion. As smartphone users increasingly use their mobile 
devices to access the Internet (in the UK, for example, 73% 
of adults browsed the Internet using their mobile phones in 
2017, compared to 36% in 2011), so grows the opportunity 
for health authorities to reach patients through digital chan-
nels where they are already seeking information [34].
It is not practical to expect the outputs from novel, 
patient-centric reporting channels to mimic those from 
traditional channels, particularly as the value of patient-
reported individual case safety reports (ICSRs) has only 
been recognised relatively recently [3]. There is therefore 
a need to re-calibrate expectations and perspectives when 
evaluating mechanisms for patient ADR reporting and 
establish a methodology that can allow an assessment of 
these initiatives entirely on their own, and not in the context 
of traditional reporting channels. For instance, Lareb has 
found that its Bijwerking app has encouraged participation 
from new members of the public, specifically HCPs, who 
have never submitted an ADR report previously, suggest-
ing that the existence of the mobile app has increased the 
breadth and diversity of reporters [35]. Additionally, evalua-
tion of reports originating from the apps revealed that while 
the resulting data had lower completeness scores, the app 
reports demonstrated clinical quality that did not differ sig-
nificantly from that of reports submitted via conventional 
reporting channels and contributed to signal detection and 
safety evaluation activities.
Probably the most important recommendations are those 
that relate to engagement of users of the app, in particular, 
establishing the two-way interchange of safety information. 
Users of the app valued the provision of graphs and charts 
showing the safety profile of their medicines. This posi-
tive reinforcement of the value of transmitting ICSR was a 
feature of the feedback received during focus groups and 
interviews. However, a commitment to provide automated 
feedback should not override the current practices in terms 
Table 6  Recommendations on assessment of the overall impact of applications (apps) for pharmacovigilance and other stand-alone recommen-
dations
ADR adverse drug reaction, HCP healthcare professional
Recommendation Rationale
The app should be considered an additional channel for ADR reporting Analysis has shown very little qualitative difference between reports 
from ‘conventional means’ and reports from the app [25]
Consideration could be given to having the app tested by an independent 
reviewer that specialises in health apps prior to launch
Some countries have healthcare specific app stores that contain apps 
that have been tested by the relevant national health services and cer-
tified for usability, utility, and security. This can generate confidence 
in and increase awareness of the app
Consideration should be given to the means of measuring the public 
health impact of the app after launch with HCPs and patients
Measuring the impact of any mobile app can be challenging. It is 
easy to capture the number of downloads or reports, although these 
figures do not provide insights into the value of news feeds and 
safety data to patients or the value provided to HCPs and whether it 
impacts their prescribing. Valuable metrics may include:
 How often reports are sent
 How often the app is opened, how many new downloads, how many 
ADRs reported
 Impact of signals arising from the app compared to traditional report-
ing mechanisms
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of providing feedback for other reporting routes [22]. In gen-
eral, provision of more detailed feedback information should 
be well thought through, as it may introduce questions or 
concerns relating to the complexity of mandatory ADR 
reporting requirements that may require time to address.
Equally important was the protection of data privacy, 
in accordance with national and European laws. Patients 
wanted assurance that the highest standards of confidenti-
ality were maintained during the data reporting and trans-
fer processes. Patients also found it important to be able to 
review their own previously submitted reports and to submit 
corrections or follow-up information later, if needed. Over-
all, the app and surrounding publicity brought the impor-
tance of PV to the attention of various stakeholders in public 
health. In the case of HCPs, this served as a reminder to 
report suspected ADRs, but for patients and caregivers, the 
app provided an alerting mechanism, highlighting the value 
of the public in recognising potential safety concerns.
The app could be considered an important mechanism to 
facilitate compliance with the European Union PV frame-
work legislation which became operational in July 2012, 
obliging all NCAs and MAHs to record and report cases of 
suspected ADRs received from patients. Careful consultation 
with a range of patients and patient support groups helped 
in the design and delivery of a functional app to facilitate 
patient reporting. An app provides an additional means of 
reporting suspected ADRs and communication and, further-
more, projects an innovative and progressive image; in turn 
this fosters engagement with stakeholders. Health authorities 
might consider providing an app as an additional means of 
reporting and/or communication; however, the value versus 
opportunity costs, which were not specifically evaluated in 
WEB-RADR, are likely to vary from country to country. It is 
important that regulators are accessible through means that 
patients and HCPs use in their day-to-day lives; it should not 
be any more challenging to report an ADR than to use any 
other service. Furthermore, responsiveness to new technolo-
gies projects an innovative and progressive image that in 
turn fosters trust and improves dialogue with stakeholders.
A maintenance and support programme has been estab-
lished with the aim of ensuring the sustainability of the app; 
however, questions remain about its long-term utility. From 
the patient perspective, there may be no need to repeatedly 
use the app to submit an ADR report; many patients will not 
experience multiple ADRs (if at all); thus, most users will 
not find it necessary to keep the app on their device, let alone 
use it regularly. Conversely, for HCPs, the app may prove 
useful on multiple occasions and could be of even greater 
utility if the app was integrated with other software, such as 
prescribing records, dispensing systems and other healthcare 
systems. The WEB-RADR project has established a follow-
up programme to develop the app using additional medical 
ontology mappings and by evaluating additional application 
programming interfaces for linking to other software.
In the future, the potential value of the app in support-
ing the notification of product quality issues and/or product 
complaints should be investigated. This could yield impor-
tant information about manufacturing issues or batch-related 
concerns, particularly if used in conjunction with built-in 
image capture technologies. Similarly, specialist use of the 
app should be considered if an emerging safety issue arises 
with a product or class of medicines. Any situation such 
as this would require the close monitoring of a cohort of 
patients in a defined setting, and the app could provide a 
useful adjunct to traditional methods of PV by providing 
safety data in real time for rapid evaluation.
4  Conclusions
Over a period of 3 years, IMI WEB-RADR has addressed 
several important research questions relevant to the develop-
ment of an app for reporting suspected ADRs. The resultant 
recommendations point to a series of pragmatic steps that 
those working in the PV community should consider before 
designing and building an app in support of safety report-
ing. The recommendations support the idea that the app is 
an important adjunct to existing ADR reporting pathways; 
however, engagement of app users is key to successful app 
development and adoption, in particular, in establishing the 
two-way interchange of safety information. As a younger 
generation of app-literate patients matures, it seems likely 
that app-based reporting will grow in importance and that, 
at some point, structured electronic reports will supplant the 
use of traditional paper forms.
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